1. Interleukin 6 gene polymorphism is associated with protein serum level and disease activity in Polish patients with rheumatoid arthritis.
- Author
-
Wielińska J, Dratwa M, Świerkot J, Korman L, Iwaszko M, Wysoczańska B, and Bogunia-Kubik K
- Subjects
- Adult, Aged, Alleles, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid immunology, Case-Control Studies, Female, Gene Expression, Gene Frequency, Humans, Interleukin-6 blood, Interleukin-6 immunology, Male, Middle Aged, Poland, Severity of Illness Index, Tumor Necrosis Factor-alpha antagonists & inhibitors, Tumor Necrosis Factor-alpha blood, Tumor Necrosis Factor-alpha genetics, Tumor Necrosis Factor-alpha immunology, Arthritis, Rheumatoid genetics, Genetic Predisposition to Disease, Homozygote, Interleukin-6 genetics, Polymorphism, Single Nucleotide
- Abstract
Interleukin 6 (IL-6) is a pro-inflammatory cytokine involved in the development of rheumatoid arthritis (RA). The present study aimed to determine the possible association of the IL6 (rs1800795, G > C) polymorphism with RA susceptibility, disease progression and protein serum levels. Distribution of IL6 alleles and genotypes was similar in RA patients and controls. As expected, patients before induction of anti-tumour necrosis factor agents had significantly higher IL-6 levels as compared with controls (P = 0.002). The CC homozygous patients were characterised with the highest average concentrations of this pro-inflammatory cytokine before treatment (P = 0.028), and they also more frequently presented with more active disease (P = 0.048). These results imply that the IL6 rs1800795 CC homozygosity may play a rather unfavourable role in RA., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF